← Launch hub

Nootropic Pouches Launch · Slot 03

VALUE 3 · REVEAL

revealThu Oct 29 · 11:00 ETAnnouncement blog
EM-284 · #3 Nootropic Pouches - Product Announcement Blog →Built on: #4 Protein Coffee - Product Announcement Blog · Oct 5, 2026 · RPR $0.069 (read 2026-10-20) →Launch history →← Prev: slot 02Next: slot 04 →
Statusbrief open; copy, build, GlockApps and scheduling to comehover to open · click to pin
BriefCopyBuildGlockAppsScheduled
The send, and what it exploresthe reveal: product named for the first time; every claim gate must clear first

Subject (approved): “This is for you, {first_name}!”

The reveal. The product and the format are named for the first time: a pouch with no nicotine in it, both SKUs and every dose as the concept page prints them, against a named rival that prints none. No 'safer than ZYN', no cessation promise. Needs the product name and the container word (open on canon).
Research brief & gatesthe research, and what it is not allowed to say

Product named, first time; the format said for the first time. Both SKUs and every dose exactly as canon prints them; no nicotine in either; prices as targets; the product name and the container word are OPEN on canon and must be settled before this ships.

The answer to the arc

Values 1 and 2 opened the trade (nicotine's focus is partly its own withdrawal; the companies and the states are paid for it). The reveal answers: a pouch with no nicotine in it, every milligram printed. We do not call it safer than ZYN (the FDA reviewed ZYN for years; our finished pouch has no such record) and we do not promise to get anyone off nicotine.

The rival, by name

Ultra (takeultra.com) runs 101 live US ads, 16 naming paraxanthine, none printing a dose. The concept page's July Amazon read lists 'Ultra Focus' at 100 mg; verify same company before any 100-vs-200 line prints.

The field it enters

430 live US pouch ads from 23 brands: focus 44.9%, nicotine replacement 41.2%, clean energy 7.4%, caffeine-free 3.5% (one brand), the dose on the label 0.7%. Per-pouch price at the targets is ~2.5× the field's (dossier §7).

  • Every number from a primary source, fetched and read, before it reaches copy.
  • Generic ingredient names only. Cognizin, TeaCrine and enfinity are competitor language.
  • SKU-002 is caffeine-free, never stimulant-free.
  • No cessation framing: never 'quit', 'replace your nicotine', 'wean'. Customers' own words may be quoted with a permalink.
  • 'Dietary supplement' and Supplement Facts language are gated until counsel answers the DSHEA ingestion question (dossier §8b).
  • Prices print as targets until Juan locks them; the formula is the concept page until a label exists.
  • Never attack caffeine, sweeteners, glycerin or 'synthetic' as a category: the product carries all of them.
  • Alt text five words or fewer; GlockApps preflight on subject and wrapper before scheduling.
Imagery direction & referencesreferences, thumbnails and swipe fuel

The product and the label, every milligram readable at arm's length. The rival's creative: Ultra in the gallery; the caffeine-free set. Container word and name pending.